MEDNAX's (MD) Q2 Earnings Surpass Estimates, Decline Y/Y

MEDNAX, Inc. MD reported second-quarter 2020 adjusted earnings of 32 cents per share, beating the Zacks Consensus Estimate by 113.3%. However, the bottom line plunged 64% year over year due to muted revenues.

The company’s results were negatively impacted by the COVID-19 pandemic. In fact, the coronavirus outbreak dented patient volumes as well as revenues. The impact on net revenues was maximum during April.

Quarterly Details

The company generated revenues of $509 million, which missed the Zacks Consensus Estimate by 13.9%. Also, the top line declined 41.4% from the year-ago period. This was due to major reductions in patient volumes as a result of the prevalent COVID-19 pandemic.

Same unit revenues dropped 11.7% year over year.

General and administrative expenses fell 7.7% to $77.7 million on the back of lower general and administrative expenses.

Interest expense of the company declined 9% to $28.3 million on the back of lower borrowings.

In the quarter under review, EBITDA totaled $65.2 million, down 30.8% year over year.

MEDNAX, Inc. Price, Consensus and EPS Surprise

MEDNAX, Inc. Price, Consensus and EPS Surprise

MEDNAX, Inc. price-consensus-eps-surprise-chart | MEDNAX, Inc. Quote

Financial Update

As of Jun 30, 2020, the company had cash and cash equivalents of $132.2 million, up 22.5% from the level as of Dec 31, 2019.

The company’s total debt of $1.7 billion was up 0.5% from the level at 2019 end while total assets worth $3.4 billion were down 18.3% from the level at last-year end.

Cash flow generated from operating activities was $193.4 million in the quarter under review, jumping 172% year over year.

Business Update

MEDNAX completed the sale of its anesthesiology medical group American Anesthesiology to North American Partners in Anesthesia (NAPA).

The company intends to divest MEDNAX Radiology Solutions and return to its original name, Pediatrix Medical Group, Inc. It aims to channelize its resources as a pediatrics and obstetrics organization.

Zacks Rank

MEDNAX currently carries a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Other Medical Sector Releases

Of the medical sector players that have reported second-quarter results so far, earnings of UnitedHealth Group Incorporated UNH, HCA Healthcare, Inc. HCA and Universal Health Services, Inc. UHS beat the Zacks Consensus Estimate.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Click to get this free report

UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

Universal Health Services, Inc. (UHS): Free Stock Analysis Report

HCA Healthcare, Inc. (HCA): Free Stock Analysis Report

MEDNAX, Inc. (MD): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More